dimensional model of the instrument with group type (exercise or control) as the criterion variable to assess model invariance. RESULTS: A total of 89 participants completed the trial of which 48 were in the exercise group. Evidence of variation in the factorial structure of the EPDS between groups was found suggesting the invariance assumption may not be supported. CONCLUSIONS: The assumption that the outcome measure (EPDS) is invariant between groups within an RCT was not supported. Further investigation is required to evaluate the impact of outcome measure variance on treatment effects in clinical trials where self-report measure data is used as primary and/or secondary outcomes.

**INDIVIDUAL’S HEALTH – Cost Studies**

**PHI9**

**TRENDS IN IUD INSERTIONS AND RELATED MEDICAL EXPENDITURE IN THE UNITED STATES: THE POPULATION WITH EMPLOYER-SPONSORED INSURANCE**

**Xu X, Placulous M, Ouyang L, Grosse S**

Centers for Disease Control and Prevention, Atlanta, GA, USA

**OBJECTIVES:** The prevalence of intrauterine device (IUD) use is low among women of reproductive age in the United States. The objective of this study was to examine the trend in IUD insertions and related medical expenditures between 2002 and 2007 in a population of women covered by employer-sponsored health insurance (ESI). METHODS: We conducted a population-based study using the MarketScan Commercial Claims and Encounter Enrolled Population Database. We identified women 15–49 years old who filed a claim for the insertion of an IUD or IUS (the Leonov, estrel-releasing IUD) between January 1, 2002 and December 31, 2007. We adopted the MarketScan national weights in order to generate nationally representative estimates. RESULTS: The number of new IUD/IUS patients in the ESI-covered population doubled, from 70,851 (2/1,000 eligible women) in 2002 to 154,366 (8/1,000) in 2007. Meanwhile, the market share of the IUS increased from 35% to 80% of all IUD insertions. The mean copayment for IUD (EIS) devices decreased from $13.0 ($14.6) in 2002 to $3.5 ($3.6) in 2007 after adjusting for inflation (in 2007 dollars), and the percent of patients with zero copayment for the device and for the insertion procedure increased from 65% to more than 80% and form 58% to 73%, respectively. The average net reimbursement for the IUD increased 17.5% between 2002 and 2007, from $311.92 to $366.64, while that for the IUS increased 7.5%, from $405.36 to $435.49. CONCLUSIONS: The increase in medical expenditures associated with IUD/IUS insertions from 2002 to 2007 was driven by the growth in IUS insertions. IUDs have lower contraceptive failure rates than other reversible contraceptive methods, and higher rates of IUD use should lead to fewer unwanted pregnancies. Additional research is needed to understand whether the recent growth in IUS insertions is related to changing provider attitudes and more favorable insurance coverage.

**PHI10**

**TREATMENT PATTERNS AND ECONOMIC BURDEN OF UTERINE FIBROIDS IN A UNITED STATES MANAGED CARE DATABASE**

**Bapst D, Davis K, Bell KF, Deal LS, Talbird SE**

RTI Health Solutions, Research Triangle Park, NC, USA, 1Abt Bio-Pharma Solutions, Inc, Lexington, MA, USA, 2Abt Bio-Pharma Solutions, Inc, Lexington, MA, USA, 3Eli Lilly and Company, Indianapolis, IN, USA

**OBJECTIVES:** To document surgical treatment patterns of uterine fibroid (UF) patients and total all-cause medical costs for UF patients in real-world practice settings using data from a national managed care database. METHODS: A total of 802 women with a UF diagnosis between 15 and 51 years of age were selected between 2000 and 2006. An index date was defined as the date of first observed UF diagnosis. All patients were required to have continuous plan enrollment 6 months pre- and 36 months post-index date. Summary statistics for patient characteristics, probability of first UF-related surgery, any repeat UF-related surgery, and total medical and pharmacy costs (2007 US$) incurred 12 months post-index date were generated. RESULTS: A total of 109,595 patients met the study inclusion criteria. The mean age at UF diagnosis was 43 years and the mean Charlson score was 0.2. Patients with commercial insurance accounted for 91% of the population, while 7% had an HMCO or PPO plan. The probability of UF-related surgery was 30.2%, 35.0%, and 38.4% within the 12-month, 24-month, and 36-month follow-up periods, respectively. Among patients with a UF-related surgery during the 36 month follow-up period, 79.6%, 7.3%, 3.1%, 13.0% had hysterectomy, myomectomy, UAE/UAI, and ablation, respectively. Mean age at first surgery (44 years) varied by surgery type with younger women more likely to undergo myomectomy. The rate of repeat surgery within one year of first surgery ranged from 4.6% (hysterectomy) to 10.5% (ablation). The mean total cost for all UF patients was $960.8, 12 months post-index date. CONCLUSIONS: A substantial proportion of patients underwent UF-related surgeries within one to three years of diagnosis, with hysterecctomy being the most common surgery. UF-related surgeries present significant clinical and economic implications that should be understood by private and public third party payers who bear the financial burden of UF surgical care.

**PHI11**

**THE BURDEN OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) ON PATIENTS HOSPITALIZED WITH A PRIMARY DIAGNOSIS OF OPPOSITIONAL DEFiant DISORDER (ODD)**

**Massey L, Clausi P, Wrona LA, Cruikshank A, Cunningham S, Carter D**

RTI Health Solutions, Research Triangle Park, NC, USA, 1Eli Lilly and Company, Indianapolis, IN, USA

**OBJECTIVES:** To assess lengths of stay (LOS) and costs attributable to ADHD among adolescents hospitalized with a primary diagnosis of ODD. METHODS: Patients 12–17 years old with a primary diagnosis of ODD (ICD-9-CM code 313.81) were selected from the 2000 to 2006 Health care Cost and Utilization Project Nationwide Inpatient Sample (HCUP-NIS). Patients with a diagnosis of ADHD (ICD-9-CM codes 314.01 and 314.01) comprised the study cohort and patients without an ADHD diagnosis comprised the control cohort. Study measures included demographics, hospital characteristics, admission source, discharge disposition, LOS, and costs. Generalized linear models accounting for the HCUP-NIS survey design were undertaken to adjust LOS and cost estimates. RESULTS: A total of 7,464 and 3,039 patients met the inclusion criteria for the study and control cohorts, respectively. Patients in the study cohort were 6.8 months younger than patients in the control cohort (13.8 versus 14.4 years). A higher percentage of patients in the study cohort were male (71.4% versus 45.2%) or had Medicaid (57.1% versus 48.6%) compared to the control cohort. In both cohorts, the ER was the most common admission source, approxi- }

**PHI12**

**DULOXETINE DOSING PATTERNS AND HEALTH CARE COSTS AMONG ELDERLY DIAGNOSED WITH FIBROMYALGIA**

**Wu N, Chen SY, Yao P, Boulanger L, Peng X, Zhao Y**

AbbVie, North Chicago, IL, USA, 2AbbVie BioPharma Solutions Inc, Lexington, MA, USA

**OBJECTIVES:** This study employed a retrospective cohort design to examine patterns of duloxetine utilization and health care costs among elderly fibromyalgia patients. METHODS: All duloxetine claim data were analyzed for patients aged 65+ with Medicare supplemental insurance who initiated duloxetine in 2006. The index date was defined as the dispense date of the first duloxetine prescription filled, with no duloxetine coverage in the prior 90 days. Patients were required to have at least 30 supply days of duloxetine in the 12 months post-index period. Individuals with any diagnosis of diabetic peripheral neuropathic pain or depression during the 12 months pre-index period were excluded. Five study cohorts were constructed based on the index dosage: <30 mg, 30–39 mg, 30 mg, 30–59 mg, 60 mg, and >60 mg. Patterns of duloxetine use including changes in dosage, average daily dose (ADD), adherence to dulox- etine (medication possession ratio ≥0.8 as high adherence) were examined across study cohorts. Regression models were performed to estimate the differences in health care costs. RESULTS: A total of 356 fibromyalgia patients were included, with 41, 163, 37, 219, and 32 in the <30 mg, 30–39 mg, 30 mg, 30–59 mg, 60 mg, and >60 mg cohorts, respectively. A total of 31.4% of patients experienced any dosage changes (increased dosage: 25.8%; decreased dosage: 15.7%). Among those who changed dosage, patients in the 30–39 mg cohort had the shortest time to change (81 days); and patients in the <30 mg cohort had the longest (149 days) time. ADD trended upward as index dose increased. Compared with patients in the 60 mg cohort, those in the <30 mg and >60 mg cohorts were less likely to be adherent (odds ratios 0.40 and 0.30, respectively, both p < 0.05). Post-index total health care costs were similar across cohorts. CONCLUSIONS: Dosage changes occurred most quickly in fibromyalgia patients with an index dose of 31–59 mg of duloxetine. Duloxetine ADD and adherence differ by index dosage, while health care costs remain similar.

**PHI13**

**HEALTH CARE UTILIZATION AND COSTS FOR THE TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER**

**Palmer L, Johnson BH, Foley D**

Thomson Reuters, Washington, DC, USA, 2Boehringer Ingelheim, Ridgefield, CT, USA

**OBJECTIVES:** Hypoactive sexual desire disorder (HSDD) is characterized by persistent/recurring deficiency of sexual fantasies or thoughts, and/or the absence of desire for sexual activity. Despite the potentially high prevalence of the condition, few studies have evaluated the cost of treating women with HSDD. The current study describes health care utilization and costs among women suffering from HSDD relative to women without evidence of female sexual dysfunction (FSD). METHODS: Women aged 18–64 with a diagnosis of HSDD (ICD-9-CM: 302.71) were identified using the Marketscan® Commercial Claims and Encounters Databases from Thomson Reuters. Women were identified between January 1, 1998 and December 31, 2007 and were matched 1:3 to women without FSD (ICD-9-CM: 302.7x; 306.51) based on age, health plan type and months with medical/pharmacy benefits. Utilization and costs were evaluated during the 12, 24 and 36-month periods following HSDD diagnosis.

**Abstracts**